)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Shield Therapeutics (STX) investor relations material
Shield Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary3 Sep, 2025
Executive summary
Revenues for H1 2025 rose 1.8x year-over-year to $21.4 million, driven by US ACCRUFERⓇ sales and higher net selling prices.
ACCRUFERⓇ prescriptions in the US reached approximately 84,000, up 1.3x from H1 2024, with a 1.4x increase in average net selling price to $214.
Global expansion advanced with launches and regulatory progress in Canada, Japan, China, and pediatric filings in the US and Europe.
Loss for H1 2025 narrowed to $9.5 million from $15.5 million in H1 2024, reflecting revenue growth and cost control.
Cash position strengthened to $10.8 million, supported by a $10 million equity raise and milestone payments.
Financial highlights
US ACCRUFERⓇ revenue: $19.2 million, up from $11.0 million in H1 2024.
Ex-US revenue: $2.2 million from milestones and royalties, up from $1.1 million.
Cost of sales increased to $10.9 million (H1 2024: $6.7 million).
Selling, general, and administrative expenses decreased to $15.6 million (H1 2024: $18.8 million).
Net cash outflow from operations was $1.7 million, improved from $3.6 million in H1 2024.
Outlook and guidance
Guidance to achieve cash flow positivity by end of 2025 remains unchanged.
Continued US prescription growth and further improvement in financial metrics expected in H2 2025.
Anticipated regulatory approvals for pediatric and China markets in 2026.
What drove H1 2025 operating cash outflow?
How did consignment reduction boost net price?
China ACCRUFER approval timeline and value?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Shield Therapeutics earnings date
H2 202523 Apr, 2026
Next Shield Therapeutics earnings date
H2 202523 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Shield Therapeutics plc is a specialty pharmaceutical company focused on the development and commercialization of treatments for iron deficiency and related conditions. The company's lead product, Accrufer/Feraccru® (ferric maltol), is an oral iron therapy designed to treat iron deficiency in patients who cannot tolerate traditional iron supplements. Shield Therapeutics operates in Europe and the United States, partnering with healthcare providers and pharmaceutical distributors to expand its market reach. The company is headquartered in Gateshead, United Kingdom, and its shares are listed on the AIM.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage